Oncocyte Corporation

🎉 Attending #ASHI2024 this week? Stop by our booth (#509) for a chance to win in our daily raffle! 🏆 Just drop your business card in the fishbowl, and you could be our next winner. Don’t miss out—come see us, enter, and stay tuned for the announcements! 🐟✨ #OCX #ASHI #Raffle #WhereTomorrowLives #OrganPlushie

🎉 #ASHI2024 annual conference kicks off this afternoon, and we can’t wait to see you there! Stop by Booth 509 to meet the team and learn how GraftAssure can bring dd-cfDNA testing to your lab. We're looking forward to connecting with fellow professionals and sharing insights all week! Don’t forget to scan the QR code to get more info about GraftAssure and all the exciting ways we can support your work. See you soon! #ASHI #ddcfDNA #GraftAssure #LabInnovation #Booth509 #Research #GraftAssure #OCX #WhereTomorrowLives $OCX

🌍 Safety First at Oncocyte! 🌍 Today, Oncocyte participated in The Great ShakeOut earthquake drill at both our Irvine and Nashville offices. 🌟 Our teams practiced essential safety measures, reinforcing our commitment to the well-being of our employees, partners, and communities. Preparedness is key, and this drill helps ensure that we're ready to respond swiftly and effectively in the event of an emergency. A huge thank you to everyone who took part, demonstrating that safety remains our top priority. Together, we’re building a safer, more resilient workplace! 💪🔗 #SafetyFirst #EarthquakePreparedness #GreatShakeOut #Oncocyte

Exciting news! Oncocyte Corporation announces its latest publication in the American Association for Cancer Research Journal, highlighting DetermaIO’s predictive potential. The NeoTRIPaPDL1 study found that DetermaIO predicted selective benefit from ICI therapy in triple-negative breast cancer, demonstrating a significant impact on patient outcomes. “We are thankful for the support from Dr. Matteo Dugo and his team, and are thrilled that the data in this clinical trial and this publication clearly demonstrate that DetermaIO can identify patients who are more likely to benefit from immunotherapy,” Oncocyte CEO Josh Riggs said. “DetermaIO continues to outperform standard of care biomarkers and assays. ” #PressRelease #DetermaIO #LifeSaving #Publication #NeoTRIPPDL1Study #PatientCare #OCX #WhereTomorrowLives $OCX Click here to find out more: https://hubs.li/Q02SCCyw0

🌟 Join Oncocyte Corporation at the ASHI's 50th Annual Meeting in Anaheim, CA from Oct. 21-25! 🌟 We're excited to sponsor this year's event. Visit us at booth #509 to learn more about GraftAssure and to meet our team: > Ryan Andrews, VP Commercial > Geoff Bien, Director, Product Market Development > Jim Fee, Associate Director, Product Market Development > Joe Hunter, National Director, Transplant Commercial Operations > Jason McDowell, Clinical Liaison & Product Development Leader > Paul Muncy, Clinical Liaison & Product Development Leader > Ana (DeBare) Schuetz, Sr. Product Manager, Transplant > Julie Walker, Associate Director, Marketing Click this link to connect with us: https://hubs.li/Q02SpVWt0 Or simply scan the QR code in the graphic. AMERICAN SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS (ASHI) #ASHI2024 #50thAnnualMeeting #JoinUs #OCX $OCX

Our Ops team recently enjoyed an exciting axe-throwing event in Nashville, and it was a hit! 🪓 It’s always great to step away from the day-to-day, bond as a group, and sharpen our skills (literally and figuratively 😉). From cheering each other on to hitting bullseyes, this was a fantastic way to strengthen our team spirit and collaboration. It's a nice reminder of how important teamwork and a little friendly competition are in building stronger connections. At Oncocyte, we believe that fostering a positive and connected culture is key to our success, both in and out of the workplace. #TeamBuilding #CompanyCulture #Nashville #WorkHardPlayHard #AxeThrowing

Oncocyte Corporation is thrilled to be a sponsor of the 2024 hubXchange, Immuno-Oncology Xchange, in San Francisco! 🎉 Join us where leaders in #immunobiology come together to share the latest #advancements and #innovations. 📢 We are also excited for our very own Tyler Nielsen, Sr. Scientist, Product Development, who will be presenting: 🗓 Date: Today, Sept. 24th 🕛 Time: 3:15 PM 🎤 Title: Deciphering the Tumor Immune Microenvironment: A Novel Biomarker to Predict Immunotherapy Outcomes. Don’t miss Tyler’s presentation. It's a must-attend for anyone interested in the future of cancer treatment! 😉 We look forward to seeing you there! #OCX #HubXchange2024 #CancerResearch #Immunotherapy #Biomarkers #HealthcareInnovation #ScienceForACure #WhereTomorrowLives